Overview

The Mannitol-Asthma-Ciclesonide-Study

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Response of a 4 weeks treatment with daily once 320 µg ciclesonide on airway hyperresponsiveness assessed with mannitol. Hypothesis: Treatment with inhaled ciclesonide reduces airway hyper-responsiveness in 80% of hyper-responsive patients compared to 20% only in the placebo group and the group without airway hyper-responsiveness.
Phase:
Phase 4
Details
Lead Sponsor:
Cantonal Hosptal, Baselland
Treatments:
Ciclesonide
Mannitol